JSI-1187

Other Medications

Description

JSI-1187 is an experimental drug currently being studied in clinical trials for certain advanced solid tumors. It is being investigated as a potential treatment for cancers that have specific mutations in the MAPK pathway, including the BRAF V600E mutation. In clinical trials, JSI-1187 has been tested alone (monotherapy) and in combination with another drug called dabrafenib. The trials are designed to determine the appropriate dose and evaluate the safety and effectiveness of JSI-1187 in patients whose tumors have these specific mutations. It is taken orally, usually in a fasted state.

Mechanism of Action

JSI-1187 is being studied for its potential to target the MAPK pathway, which is involved in cell growth and division. This pathway can become overactive in certain cancers, leading to uncontrolled growth. JSI-1187 is designed to interfere with this pathway. The specific molecular target of JSI-1187 is being investigated in clinical trials.

Side Effects

JSI-1187 is still in early-phase clinical trials (Phase 1). Therefore The full range of potential side effects is still being evaluated. Information from the trial description indicates that studies are monitoring for toxicities related to the drug. As it is an investigational drug Specific common side effects are not yet established. Patients participating in trials are closely monitored for any adverse events.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT04418167 Phase 1

Suspended

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

United States

Quick Info

Category	Other Medications
Clinical Trials	1

View Clinical Trials Back to Drug Glossary

Related Medications

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.